

XPH

SPDR S&P Pharmaceuticals ETF

Analyst Report

This ETF is one of several options for investors looking to establish exposure to the U.S. pharmaceutical industry, a sub-sector of the health care space that can post big returns during periods of consolidation or as a result of advancements in medicine. Given this narrow focus, XPH probably doesn't belong in a long-term portfolio, though it may be useful for covering a corner of the domestic equity market that receives minimal weight in most portfolios. XPH is noteworthy because of the methodology employed by the underlying index; as an equal-weighted benchmark, this fund offers balanced exposure to the pharma sector, avoiding the potential pitfalls of cap-weighted benchmarks. This equal-weighted methodology distinguishes XPH from other pharma ETFs, such as PJP, PPH, and IHE.

ESG Themes and Scores

6.01/10

ESG Rate

39.44%

Global Percentile

36.66%

Peer Percentile

Performance Data

	XPH	ETF Database Category Average	Factset Segment Average
1 Month	3.11%	6.36%	2.12%
3 Month	-10.83%	-3.37%	-6.08%
YTD Return	-6.06%	-5.26%	-5.98%
1 Year Return	-8.78%	-6.98%	-6.93%
3 Year Return	-6.94%	-5.13%	-0.32%
5 Year Return	-1.01%	2.38%	2.53%

Top 5 Holdings

Symbol	Holding	% Assets
ELAN	Elanco Animal Health, Inc.	5.50%
ITCI	Intra-Cellular Therapies, Inc.	5.19%
LLY	Eli Lilly and Company	4.98%
RPRX	Royalty Pharma Plc Class A	4.88%
ZTS	Zoetis, Inc. Class A	4.85%

Vitals

Issuer	State Street
Brand	SPDR
Structure	ETF
Expense Ratio	0.35%
Inception	Jun 19, 2006
Index Tracked	S&P Pharmaceuticals Select Industry Index

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Blend
Region (General)	North America
Region (Specific)	U.S.

FactSet Classifications

Segment	Equity: U.S. Pharmaceuticals
Category	Sector
Focus	Health Care
Niche	Pharmaceuticals
Strategy	Equal
Weighting	Equal

